Exhibit 10.1


 


Execution


 


Subscription Agreement


 


THE SECURITIES HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER
RESTRICTIONS ON THE TRANSFERABILITY OF THE SECURITIES DESCRIBED HEREIN.


 


THE PURCHASE OF THE
SECURITIES INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEAR THE RISK OF THE LOSS OF THEIR ENTIRE
INVESTMENT.


 


HEALTHLYNKED CORP.


1265
Creekside Parkway Suite 302


Naples,
Florida 34108


 


Ladies and Gentlemen:


 


The undersigned understands
that HEALTHLYNKED CORP., a corporation organized under the laws of Nevada (the "Company"), is offering an aggregate
of 7,692,308 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”),
and warrants to purchase 3,846,154 shares of Common Stock (the “Warrants”, and together with the Shares, the
"Securities") in a private placement. The undersigned further understands that the offering is being made without
registration of the Securities under the Securities Act of 1933, as amended (the "Securities Act"), or any securities
law of any state of the United States or of any other jurisdiction, and is being made only to "accredited investors"
(as defined in Rule 501 of Regulation D under the Securities Act).


 


1. Subscription.
Subject to the terms and conditions hereof, the undersigned hereby irrevocably subscribes for the Securities set forth in Appendix
A hereto for the aggregate purchase price set forth in Appendix A, which is payable as described in Section 4 hereof. The
undersigned acknowledges that the Securities will be subject to restrictions on transfer as set forth in this subscription agreement
(the "Subscription Agreement").


 


2. Acceptance
of Subscription and Issuance of Securities. It is understood and agreed that the Company shall have the sole right, at its
complete discretion, to accept or reject this subscription, in whole or in part, for any reason and that the same shall be deemed
to be accepted by the Company only when it is signed by a duly authorized officer of the Company and delivered to the undersigned
at the Closing referred to in Section 3 hereof. Notwithstanding anything in this Subscription Agreement to the contrary,
the Company shall have no obligation to issue any of the Securities to any person who is a resident of a jurisdiction in which
the issuance of Securities to such person would constitute a violation of the securities, "blue sky" or other similar
laws of such jurisdiction (collectively referred to as the "State Securities Laws").


 




     


    




    

 


3. The
Closing. The closing of the purchase and sale of the Securities (the "Closing" and the date of such Closing,
the “Closing Date”) shall take place at the offices of the Company, at 10:00 a.m. Eastern Time on February 26,
2021 or at such other time and place as the Company may designate by notice to the undersigned.


 


4. Payment
for Securities. Payment for the Securities shall be received by the Company from the undersigned by wire transfer of immediately
available funds or other means approved by the Company at or prior to the Closing, in the amount as set forth in Appendix A hereto.
The Company shall deliver certificates representing the Securities to the undersigned at the Closing bearing an appropriate legend
referring to the fact that the Securities were sold in reliance upon an exemption from registration under the Securities Act.


 


5. Representations
and Warranties of the Company. As of the date hereof and as of the Closing, the Company represents and warrants to the undersigned
that:


 


(a) The
Company is duly formed and validly existing under the laws of Nevada, with full power and authority to conduct its business as
it is currently being conducted and to own its assets; and has secured any other authorizations, approvals, permits and orders
required by law for the conduct by the Company of its business as it is currently being conducted.


 


(b) The
Company has all requisite power and authority to issue and sell the Securities, enter into this Subscription Agreement and to perform
all the obligations required to be performed by it hereunder. The execution and delivery of this Subscription Agreement and the
Common Stock Purchase Warrant evidencing the Warrants (the “Warrant Agreement”) by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Shares and
the Warrants and the reservation for issuance and the issuance of the shares of Common Stock issuable upon exercise of the Warrants
(the “Warrant Shares”) have been duly authorized by the Company’s Board of Directors and no further filing,
consent or authorization is required by the Company, its Board of Directors or its stockholders. This Subscription Agreement and
the Warrant Agreement have been duly executed and delivered by the Company, and constitute the legal, valid and binding obligations
of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be
limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.


 






    2


    




    

 


(c) The
execution, delivery and performance of this Subscription Agreement and the Warrant Agreement by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance
of the Shares and the Warrants and reservation for issuance and issuance of the Warrant Shares) will not (i) result in a
violation of the Articles of Incorporation (as defined below) or Bylaws (as defined below) or other organizational documents
of the Company, or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would
become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations and the rules and
regulations of the OTC QB market (the “Principal Market”) and including all applicable foreign, federal, state
laws, rules and regulations) applicable to the Company or by which any property or asset of the Company is bound or
affected.


 


(d) The
issuance of the Shares and the Warrants are duly authorized and, upon issuance in accordance with the terms of this Subscription
Agreement, the Shares and the Warrants shall be validly issued and free from all preemptive or similar rights, taxes, liens and
charges and other encumbrances with respect to the issue thereof and the Shares shall be fully paid and nonassessable with the
undersigned being entitled to all rights accorded to a holder of Common Stock. As of the Closing, a number of shares of Common
Stock shall have been duly authorized and reserved for issuance which equals the maximum number of shares of Common Stock issuable
upon exercise of the Warrants. Upon exercise of the Warrants in accordance with the Warrant Agreement, the Warrant Shares will
be validly issued, fully paid and nonassessable and free from all preemptive or similar rights, taxes, liens, charges and other
encumbrances with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock.
Assuming the accuracy of each of the representations and warranties set forth in Section 6 of this Subscription Agreement,
the offer and issuance by the Company of the Securities is exempt from registration under the Securities Act.


 


(e) Neither
the Company, nor any of its affiliates, nor any person acting on its or their behalf, has engaged in any form of general solicitation
or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities. The Company
shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or brokers’ commissions
relating to or arising out of the transactions contemplated hereby. The Company shall pay, and hold the undersigned harmless against,
any liability, loss or expense (including, without limitation, reasonable attorney’s fees and out-of-pocket expenses) arising
in connection with any such claim. The Company has not engaged any placement agent or other agent in connection with the offer
or sale of the Securities.


 






    3


    




    

 


(f) None of the
Company, or any of its affiliates, nor any person acting on their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the
issuance of any of the Securities under the Securities Act, whether through integration with prior offerings or otherwise, or
cause this offering of the Securities to require approval of stockholders of the Company for purposes of the Securities Act
or any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of any
exchange or automated quotation system on which any of the securities of the Company are listed or designated for quotation.
None of the Company, or any of its affiliates, nor any person acting on their behalf will take any action or steps that would
require registration of the issuance of any of the Securities under the Securities Act or cause the offering of any of the
Securities to be integrated with other offerings for purposes of any such applicable stockholder approval provisions.


 


(g) The
Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition,
interested stockholder, business combination, poison pill (including, without limitation, any distribution under a rights agreement)
or other similar anti-takeover provision under the Articles of Incorporation, Bylaws or other organizational documents or the laws
of Nevada which is or could become applicable to the undersigned as a result of the transactions contemplated by this Subscription
Agreement, including, without limitation, the Company’s issuance of the Securities and the undersigned’s ownership
of the Securities. The Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable
any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of Common Stock or a change
in control of the Company.


 


(h) The
authorized capital stock of the Company consists of (i) 500,000,000 shares of Common Stock, of which as of the date hereof, 215,751,019
are issued and outstanding, 11,412,924 shares are reserved for issuance pursuant to the Company’s stock option and purchase
plans and 114,851,736 shares are reserved for issuance pursuant to securities (other than the aforementioned options and Warrants)
exercisable or exchangeable for, or convertible into, Common Stock and (ii) 20,000,000 shares of preferred stock, par value $0.0001
per share, of which 2,750,000 shares are designated as Series B preferred stock, of which 2,750,000 are currently issued and outstanding.
No Common Stock are held in treasury. All of such outstanding shares are duly authorized and have been, or upon issuance will be,
validly issued and are fully paid and nonassessable. None of the Company’s capital stock is subject to preemptive rights
or any other similar rights or any liens or encumbrances suffered or permitted by the Company. Except as disclosed above, there
are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock of the Company, or contracts,
commitments, understandings or arrangements by which the Company is or may become bound to issue additional capital stock of the
Company or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities
or rights convertible into, or exercisable or exchangeable for, any capital stock of the Company; (iii) there are no securities
or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; and (iv)
the Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan
or agreement. True, correct and complete copies of the Company’s articles of incorporation, as amended and as in effect on
the date hereof (the “Articles of Incorporation”), and the Company’s bylaws, as amended and as in effect on the
date hereof (the “Bylaws”), and the terms of all securities convertible into, or exercisable or exchangeable for, Common
Stock and the material rights of the holders thereof in respect thereto have heretofore been filed as part of the SEC Documents.


 






    4


    




    

 


(i) The Company
has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the
Securities Act and the Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to
Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the
Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and
documents incorporated by reference therein, and the Company’s registration statements on Form S-1 and Form S-8, being
collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.  As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the
Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. The financial statements of the Company included in
the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of
the Securities and Exchange Commission (the “Commission”) with respect thereto as in effect at the time of
filing.  Such financial statements have been prepared in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise
specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain
all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of
unaudited statements, to normal, immaterial, year-end audit adjustments.


 


(j) Since
the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent
SEC Report filed prior to the date hereof, (i) there has been no event, occurrence or development that has had or that could
reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with
past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP
or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed
or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity
securities to any officer, director or affiliate, except pursuant to existing Company stock option plans.  The Company does
not have pending before the Commission any request for confidential treatment of information.  “Material Adverse
Effect” means (i) a material adverse effect on the legality, validity or enforceability of this Subscription Agreement,
(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and its subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to
perform in any material respect on a timely basis its obligations under this Subscription Agreement.


 






    5


    




    

 


(k) There is no
action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any subsidiary or any of their respective properties before or by any court,
arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an “Action”).  Neither the Company nor any subsidiary, nor any director or officer
thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state
securities laws or a claim of breach of fiduciary duty.  There has not been, and to the knowledge of the Company, there
is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director
or officer of the Company.  The Commission has not issued any stop order or other order suspending the effectiveness of
any registration statement filed by the Company or any subsidiary under the Exchange Act or the Securities Act.


 


(l) At
the Closing, all stock transfer or other taxes (other than income or similar taxes) which are required to be paid in connection
with the issuance, sale and transfer of the Securities to be sold to the undersigned hereunder will be, or will have been, fully
paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.


 


6. Representations
and Warranties of the Undersigned. The undersigned hereby represents and warrants to and covenants with the Company that:


 


(a) General.


 


(i) The
undersigned has all requisite authority to purchase the Securities, enter into this Subscription Agreement and to perform all the
obligations required to be performed by the undersigned hereunder, and such purchase will not contravene any law, rule or regulation
binding on the undersigned or any investment guideline or restriction applicable to the undersigned.


 






    6


    




    

 


(ii) The
undersigned is a resident of the state set forth on the signature page hereto and is not acquiring the Securities as a nominee
or agent or otherwise for any other person.


 


(iii) The
undersigned will comply with all applicable laws and regulations in effect in any jurisdiction in which the undersigned purchases
or sells Securities and obtain any consent, approval or permission required for such purchases or sales under the laws and regulations
of any jurisdiction to which the undersigned is subject or in which the undersigned makes such purchases or sales, and the Company
shall have no responsibility therefor.


 


(b) Information
Concerning the Company.


 


(i) The
undersigned has access to and carefully reviewed the Company’s SEC Reports and has had an opportunity for a reasonable period
of time prior to the date hereof to obtain additional information concerning the offering of the Securities, the Company, and all
other information to the extent the Company possesses such information or can acquire it without unreasonable effort or expense.


 


(ii) The
undersigned understands and accepts that the purchase of the Securities involves various risks, including the risks outlined in
the SEC Reports and this Subscription Agreement. The undersigned represents that it is able to bear any loss associated with an
investment in the Securities.


 


(iii) The
undersigned confirms that it is not relying on any communication (written or oral) of the Company or any of its affiliates, as
investment advice or as a recommendation to purchase the Securities. It is understood that information and explanations related
to the terms and conditions of the Securities provided by the Company or any of its affiliates shall not be considered investment
advice or a recommendation to purchase the Securities, and that neither the Company nor any of its affiliates is acting or has
acted as an advisor to the undersigned in deciding to invest in the Securities. The undersigned acknowledges that neither the Company
nor any of its affiliates has made any representation regarding the proper characterization of the Securities for purposes of determining
the undersigned's authority to invest in the Securities.


 


(iv) The
undersigned is familiar with the business and financial condition and operations of the Company, all as generally described in
the SEC Reports. The undersigned has had access to such information concerning the Company and the Securities as it deems necessary
to enable it to make an informed investment decision concerning the purchase of the Securities.


 


(v) The
undersigned understands that, unless the undersigned notifies the Company in writing to the contrary at or before the Closing,
each of the undersigned's representations and warranties contained in this Subscription Agreement will be deemed to have been reaffirmed
and confirmed as of the Closing, taking into account all information received by the undersigned.


 






    7


    




    

 


(vi) The
undersigned acknowledges that the Company has the right in its sole and absolute discretion to abandon this private placement at
any time prior to the completion of the offering. This Subscription Agreement shall thereafter have no force or effect and the
Company shall return the previously paid subscription price of the Securities, without interest thereon, to the undersigned.


 


(vii) The
undersigned understands that no federal or state agency has passed upon the merits or risks of an investment in the Securities
or made any finding or determination concerning the fairness or advisability of this investment.


 


(c) Non-reliance.


 


(i) The
undersigned represents that it is not relying on (and will not at any time rely on) any communication (written or oral) of the
Company, as investment advice or as a recommendation to purchase the Securities.


 


(ii) The
undersigned confirms that the Company has not given any guarantee or representation as to the potential success, return,
effect or benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment in the Securities. In
deciding to purchase the Securities, the undersigned is not relying on the advice or recommendations of the Company and the
undersigned has made its own independent decision that the investment in the Securities is suitable and appropriate for the
undersigned.


 


(d) Status
of Undersigned.


 


(i) The
undersigned has such knowledge, skill and experience in business, financial and investment matters that the undersigned is capable
of evaluating the merits and risks of an investment in the Securities. With the assistance of the undersigned's own professional
advisors, to the extent that the undersigned has deemed appropriate, the undersigned has made its own legal, tax, accounting and
financial evaluation of the merits and risks of an investment in the Securities and the consequences of this Subscription Agreement.
The undersigned has considered the suitability of the Securities as an investment in light of its own circumstances and financial
condition and the undersigned is able to bear the risks associated with an investment in the Securities and its authority to invest
in the Securities.


 


(ii) The
undersigned is an "accredited investor" as defined in Rule 501(a) under the Securities Act. The undersigned agrees to
furnish any additional information reasonably requested by the Company or any of its affiliates to assure compliance with applicable
U.S. federal and state securities laws in connection with the purchase and sale of the Securities. Any information that has been
furnished or that will be furnished by the undersigned to evidence its status as an accredited investor is accurate and complete,
and does not contain any misrepresentation or material omission.


 






    8


    




    

 


(e) Restrictions
on Transfer or Sale of Securities. As applies to the undersigned:


 


(i) The
undersigned is acquiring the Securities solely for the undersigned’s own beneficial account, for investment purposes, and
not with a view to, or for resale in connection with, any distribution of the Securities. The undersigned understands that the
Securities have not been registered under the Securities Act or any State Securities Laws by reason of specific exemptions under
the provisions thereof which depend in part upon the investment intent of the undersigned and of the other representations made
by the undersigned in this Subscription Agreement. The undersigned understands that the Company is relying upon the representations
and agreements contained in this Subscription Agreement (and any supplemental information) for the purpose of determining whether
this transaction meets the requirements for such exemptions.


 


(ii) The
undersigned understands that the Securities are "restricted securities" under applicable federal securities laws and
that the Securities Act and the rules of the Commission provide in substance that the undersigned may dispose of the Securities
only pursuant to an effective registration statement under the Securities Act or an exemption therefrom, and the undersigned understands
that other than as set forth in Section 10, the Company has no obligation or intention to register any of the Securities.


 


(iii) The
undersigned agrees: (A) that the undersigned will not sell, assign, pledge, give, transfer or otherwise dispose of the Securities
or any interest therein, or make any offer or attempt to do any of the foregoing, except pursuant to a registration of the Securities
under the Securities Act and all applicable State Securities Laws, or in a transaction which is exempt from the registration provisions
of the Securities Act and all applicable State Securities Laws; (B) that the certificates representing the Securities will bear
a legend making reference to the foregoing restrictions (subject to the legend removal requirements described below); and (C) that
the Company and its affiliates shall not be required to give effect to any purported transfer of such Securities except upon compliance
with the foregoing restrictions.


 


(iv) The
undersigned acknowledges that neither the Company nor any other person offered to sell the Securities to it by means of any form
of general solicitation or advertising, including but not limited to: (A) any advertisement, article, notice or other communication
published in any newspaper, magazine or similar media or broadcast over television or radio or (B) any seminar or meeting whose
attendees were invited by any general solicitation or general advertising.


 






    9


    




    

 


7. Conditions
to Obligations of the Undersigned and the Company. The obligations of the undersigned to purchase and pay for the Securities
specified in Appendix A and of the Company to sell the Securities are subject to the satisfaction at or prior to the Closing of
the following conditions precedent: the representations and warranties of the Company contained in Section 5 hereof and
of the undersigned contained in Section 6 hereof shall be true and correct as of the Closing in all respects with the same
effect as though such representations and warranties had been made as of the Closing.


 


8. Obligations
Irrevocable. The obligations of the undersigned shall be irrevocable.


 


9. Legend.
The certificates representing the Securities sold pursuant to this Subscription Agreement will be imprinted with a legend in substantially
the following form:


"THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR THE SECURITIES LAWS OF ANY STATE
OR OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) PURSUANT TO AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, IN
EACH CASE IN ACCORDANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AND THE SECURITIES LAWS OF OTHER JURISDICTIONS, AND IN THE CASE
OF A TRANSACTION EXEMPT FROM REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT
THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS."


 


The legend set forth
above shall be removed and the Company shall issue certificates without such legend to the holder of the Securities upon which
it is stamped or issue to such holder by electronic delivery at the applicable balance account at The Depository Trust Company
(“DTC”), if (i) such Securities are registered for resale under the Securities Act, (ii) in connection with a sale,
assignment or other transfer, such holder provides the Company with an opinion of counsel, in a generally acceptable form, to the
effect that such sale, assignment or transfer of the Securities may be made without registration under the applicable requirements
of the Securities Act, or (iii) the Securities can be sold, assigned or transferred pursuant to Rule 144. The Company shall be
responsible for the fees of its transfer agent and all DTC fees associated with such issuance.


 






    10


    




    

 


10. Piggy-Back
Registrations. If, at any time following Closing, there is not an effective registration statement covering all of the Shares
and Warrant Shares and the Company shall determine to prepare and file with the Commission a registration statement relating to
an offering for its own account or the account of others under the Securities Act of any of its equity securities (a “Piggyback
Registration Statement”), other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their
then equivalents or any other registration statement relating to equity securities issued solely in connection with any acquisition
of any entity or business as acquisition consideration (and not, for the avoidance of doubt, for purposes of financing any acquisition)
or equity securities issuable in connection with the Company’s stock option or other employee benefit plans, then the Company
shall deliver to the undersigned a written notice of such determination and, if within fifteen (15) days after the date of the
delivery of such notice, the undersigned shall so request in writing, the Company shall include in such Piggyback Registration
Statement all or any part of such Shares and Warrant Shares the undersigned requests to be registered. If a Piggyback Registration
Statement covering the Shares and Warrants Shares has not been filed and declared effective by the date that is 180 days after
the date of this Subscription Agreement, then, at the request of the undersigned, the Company shall prepare and file with the Commission
a registration statement covering the Shares and Warrant Shares (a “Demand Registration Statement” and together
with a Piggyback Registration Statement, a “Registration Statement”) and shall use its best efforts to cause
such Demand Registration Statement to be declared effective by the Commission as soon as practicable thereafter. In the case that
any Registration Statement is filed in connection with an underwritten offering, and the managing underwriter advises the Company
in writing that in its opinion the number of shares of Common Stock proposed to be included in such registration, including all
Shares and Warrant Shares and all other shares of Common Stock proposed to be included in such underwritten offering, exceeds the
number of shares of Common Stock which can be sold in such offering and/or that the number of shares of Common Stock proposed to
be included in any such registration would adversely affect the price per share of the Common Stock to be sold in such offering,
then the Company shall reduce the number of Shares and Warrant Shares registered under such Registration Statement as so advised;
provided that the Company shall still be required to register the Shares and the Warrant shares on an additional registration statement
as provided in this Section 10.


 


11. Additional
Covenants.


 


(a) The
Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary in order
to obtain an exemption for or to qualify the Securities for sale to the undersigned at the Closing pursuant to this Subscription
Agreement under applicable securities laws (or to obtain an exemption from such qualification), and shall provide evidence of any
such action so taken to the undersigned on or prior to the Closing Date. The Company shall make all filings and reports relating
to the offer and sale of the Securities required under applicable securities laws following the Closing Date.


 






    11


    




    

 


(b) The
Company shall promptly secure the listing of all of the Shares and, when issued, Warrant Shares upon each national securities exchange
and automated quotation system, if any, upon which the Common Stock is then listed (subject to official notice of issuance) and
shall maintain such listing. The Company shall maintain the authorization for quotation of the Common Stock on the Principal Market
or any other Trading Market (as defined in the Warrant Agreement). The Company shall not take any action which would be reasonably
expected to result in the delisting or suspension of the Common Stock on the Principal Market. The Company shall pay all fees and
expenses in connection with satisfying its obligations under this Section 11(b).


 


(c) So
long as the undersigned or any of its permitted transferees owns any Warrants, the Company shall take all action necessary to at
all times after the date hereof have authorized, and reserved for the purpose of issuance, no less than the number of shares of
Common Stock issuable upon exercise of the Warrants then outstanding.


 


(d) At
all times following the Closing Date, the Company shall fully comply with all current public information requirements of Rule 144
under the Securities Act.


 


12. Waiver,
Amendment. Neither this Subscription Agreement nor any provisions hereof shall be modified, changed, discharged or terminated
except by an instrument in writing, signed by the party against whom any waiver, change, discharge or termination is sought.


 


13. Assignability.
This Subscription Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.
The Company shall not assign this Subscription Agreement or any rights or obligations hereunder without the prior written consent
of the undersigned. The undersigned may assign some or all of its rights hereunder without the consent of the Company, in which
event such assignee shall be deemed to be the undersigned hereunder with respect to such assigned rights.


 


14. Waiver
of Jury Trial. EACH OF THE UNDERSIGNED AND THE COMPANY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY WITH RESPECT TO
ANY LEGAL PROCEEDING ARISING OUT OF THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT.


 


15. Submission
to Jurisdiction. With respect to any suit, action or proceeding relating to any offers, purchases or sales of the
Securities by the undersigned ("Proceedings"), each of the undersigned and the Company irrevocably submits
to the jurisdiction of the federal or state courts located in the Borough of Manhattan in New York City, which submission
shall be exclusive unless none of such courts has lawful jurisdiction over such Proceedings.


 


16. Governing
Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of New York.


 






    12


    




    

 


17. Section
and Other Headings. The section and other headings contained in this Subscription Agreement are for reference purposes only
and shall not affect the meaning or interpretation of this Subscription Agreement.


 


18. Counterparts.
This Subscription Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be
deemed to be an original and all of which together shall be deemed to be one and the same agreement.


 


19. Notices.
All notices and other communications provided for herein shall be in writing and shall be deemed to have been duly given if delivered
personally or sent by registered or certified mail, return receipt requested, postage prepaid to the following addresses (or such
other address as either party shall have specified by notice in writing to the other):


 


	 	If to the Company:	
        HealthLynked Corp.

1265 Creekside Parkway Suite 302

Naples,
        Florida 34108

         

        Facsimile: (239) 719-3434

         

        E-mail: goleary@healthlynked.com

         

        Attention:Chief Financial Officer

	 	 	 
	 	with a copy to:	
        K&L Gates LLP

        200 S. Biscayne Blvd. Suite 3900

        Miami, Fl
        33131

         

        Facsimile: (305) 358-7095

         

        E-mail: clayton.parker@klgates.com

         

        Attention: Clay Parker

	 	 	 
	 	If to the Purchaser:	
        Address:

         

        E-mail: Daniel.hall@krisdan.com

         

        Attention: Daniel Hall



 






    13


    




    

 


20. Binding
Effect. The provisions of this Subscription Agreement shall be binding upon and accrue to the benefit of the parties hereto
and their respective heirs, legal representatives, successors and assigns.


 


21. Entire
Agreement. This Subscription Agreement constitutes the entire agreement and supersedes all prior and contemporaneous agreements
and understandings among the parties with respect to the subject matter hereof and thereof.


 


22. Survival.
All representations, warranties and covenants contained in this Subscription Agreement shall survive (i) the acceptance of the
subscription by the Company and the Closing, (ii) changes in the transactions, documents and instruments described herein which
are not material or which are to the benefit of the undersigned and (iii) the death or disability of the undersigned.


 


23. Notification
of Changes. The undersigned hereby covenants and agrees to notify the Company upon the occurrence of any event prior to the
closing of the purchase of the Securities pursuant to this Subscription Agreement which would cause any representation, warranty,
or covenant of the undersigned contained in this Subscription Agreement to be false or incorrect.


 


24. Severability.
If any term or provision of this Subscription Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity,
illegality or unenforceability shall not affect any other term or provision of this Subscription Agreement or invalidate or render
unenforceable such term or provision in any other jurisdiction.


 


[SIGNATURE PAGE FOLLOWS]


 




    14


    




    

 


IN WITNESS WHEREOF, the undersigned has executed
this Subscription Agreement this 26th day of February 2021.


 


	PURCHASER (if an individual):	 	PURCHASER (if an entity):



 


	By	 	 	DanKris1, LLC 
	Name:	 	 	Legal Name of Entity



 


	SS# 	 	 






	 	By	 
	 	Name:  	 
	 	Title:  	 



 


	By:	 	 
	Name:	 	 



 


	SS#	 	 






	 	FEIN #:	 





 


State/Country of Domicile or Formation:


Aggregate Subscription Amount: US$2,000,000 Two
Million Dollars


 


The offer to purchase
Securities as set forth above is confirmed and accepted by the Company as to 7,692,308 shares of Common Stock and warrants to
purchase 3,846,154 shares of Common Stock.


 


	 	HEALTHLYNKED CORP.



 


	 	By:	 
	 	Name:	George G. O’Leary
	 	Title:	Chief Financial Officer



 






    15


    




    

 


APPENDIX
A


 


Consideration
To Be Delivered


 


	Securities to Be Acquired	 	Aggregate Purchase Price to be Paid	 
	7,692,308 shares of Common Stock and warrants to purchase 3,846,154 shares of Common Stock	 	US$	2,000,000	 



 


 


16